PharmaCell to Finalize Purchase of Cell Therapy Production Facility - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmaCell to Finalize Purchase of Cell Therapy Production Facility



PharmaCell, a CMO for cellular therapies and regenerative medicine in Europe, has finalized its purchase of the cell therapy production facility from TiGenix, a cell therapy company. TiGenix has manufactured ChondroCelect, a product for cartilage repair, at its site in Sittard-Geleen, The Netherlands, since the beginning of 2013. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with TiGenix.

Following the acquisition, PharmaCell will continue to operate its Maastricht facility in addition to the site at Sittard-Geleen. The Maastricht facility offers non-GMP process development and GMP-production facilities for early- to mid-stage clinical trials in cell therapy. The Geleen facility will offer clients the opportunity to support late stage clinical trials and commercial production for the industry.

Source: PharmaCell

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here